Development of endocrine immune-related adverse events and improved survival in advanced melanoma patients treated with nivolumab monotherapy.

[1]  K. Buder-Bakhaya,et al.  Biomarkers for Clinical Benefit of Immune Checkpoint Inhibitor Treatment—A Review From the Melanoma Perspective and Beyond , 2018, Front. Immunol..

[2]  A. Enk,et al.  Characterization of arthralgia induced by PD-1 antibody treatment in patients with metastasized cutaneous malignancies , 2018, Cancer Immunology, Immunotherapy.

[3]  Matthew D. Hellmann,et al.  Immune‐Related Adverse Events Associated with Immune Checkpoint Blockade , 2018, The New England journal of medicine.

[4]  W. Barry,et al.  Incidence of Endocrine Dysfunction Following the Use of Different Immune Checkpoint Inhibitor Regimens: A Systematic Review and Meta-analysis , 2017, JAMA Oncology.

[5]  Kaoru Tanaka,et al.  Association of Immune-Related Adverse Events With Nivolumab Efficacy in Non–Small-Cell Lung Cancer , 2017, JAMA oncology.

[6]  E. Plimack,et al.  Endocrine-related adverse events associated with immune checkpoint blockade and expert insights on their management. , 2017, Cancer treatment reviews.

[7]  H. Elhalawani,et al.  Risk of endocrine complications in cancer patients treated with immune check point inhibitors: a meta-analysis. , 2016, Future oncology.

[8]  G. Gibney,et al.  Nivolumab in Resected and Unresectable Metastatic Melanoma: Characteristics of Immune-Related Adverse Events and Association with Outcomes , 2015, Clinical Cancer Research.

[9]  Y. Fujisawa,et al.  Retrospective study of advanced melanoma patients treated with ipilimumab after nivolumab: Analysis of 60 Japanese patients. , 2018, Journal of dermatological science.

[10]  J. Soria,et al.  Association of Vitiligo With Tumor Response in Patients With Metastatic Melanoma Treated With Pembrolizumab. , 2016, JAMA dermatology.